Tryp Therapeutics, Inc. (CSE: TRYP OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the retention of IMS Investor Relations effective August 15, 2022. IMS will provide capital markets consulting, corporate communications and strategic investor outreach.
“We have made tremendous progress advancing our drug development strategy focused on attractive under-addressed indications such as eating disorders and chronic pain, and we expect to achieve multiple key strategic milestones in the second half of 2022 and into 2023. IMS Investor Relations is a well-regarded firm, and we look forward to working with them to ensure that we are proactively and productively communicating our progress to Wall Street.”
Jim Gilligan, Chief Executive Officer of Tryp Therapeutics
John Nesbett, Founder and President of IMS Investor Relations, commented, “Tryp Therapeutics is at an exciting time in their development as they continue to progress through the clinical trial process and file patents for their potentially revolutionary IP. We are pleased to partner with a company that has such a highly experienced and capable management team with a proven track record of success in the biotech space, a world-class scientific advisory board, and a potentially transformative product. We look forward to leveraging our expertise to convey Tryp’s value to investors.”
IMS will work closely with Tryp management to develop and deploy a strategic capital markets program. Initiatives are expected to include but are not limited to: refining overall company and investment-oriented messaging, ongoing strategic advise, and arranging introductions to investors and analysts in the financial community.
About Tryp Therapeutics
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. The Company has begun enrolling patients in its Phase II trial for the treatment of binge eating disorder at the University of Florida and recently announced an upcoming Phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin-based product that uses a novel formulation and route of administration to potentially improve efficacy, safety and the patient experience. For more information, please visit www.tryptherapeutics.com.